Ultragenyx Pharmaceutical (RARE) Research & Development (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Research & Development data on file, last reported at $187.0 million in Q1 2026.

• Research & Development for Q1 2026 came in at $187.0 million, up 12.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $771.2 million (up 12.5% YoY), and the FY2025 annual result was $750.0 million, up 7.45% from the prior year.
• Research & Development slipped to $187.0 million in Q1 2026 per RARE's latest filing, from $203.3 million in the prior quarter.
• Over five years, Research & Development peaked at $237.3 million in Q3 2022 and troughed at $143.2 million in Q1 2022.
• A 5-year average of $175.8 million and a median of $166.0 million in 2025 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2023: Research & Development soared 109.23% in 2022, then plunged 33.73% in 2023.
• A 5-year view of Research & Development shows it stood at $170.8 million in 2022, then slipped by 6.26% to $160.1 million in 2023, then grew by 17.36% to $187.9 million in 2024, then increased by 8.18% to $203.3 million in 2025, then declined by 8.01% to $187.0 million in 2026.
• Business Quant data shows RARE's Research & Development at $187.0 million in Q1 2026, $203.3 million in Q4 2025, and $216.2 million in Q3 2025.